Nabriva Therapeutics plc
Nabriva Therapeutics plc (NBRV): 3 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.6 months
D/E -1.65 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Nabriva Therapeutics plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$2.3M
Quarterly Burn
$5.2M
Runway
2.6 mo
Revenue
$2.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Nabriva Therapeutics plc's pipeline?
Nabriva Therapeutics plc (NBRV) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nabriva Therapeutics plc's lead drug candidate?
Nabriva Therapeutics plc's most advanced tracked candidate is contepo (Preclinical) for cUTIs, including AP.
What is Nabriva Therapeutics plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nabriva Therapeutics plc has approximately 2.6 months of cash runway.
Who is the CEO of Nabriva Therapeutics plc?
Colin Broom, MD is the chief executive officer of Nabriva Therapeutics plc (NBRV).
Get the full picture on Nabriva Therapeutics plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.